Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INVA NASDAQ:NVAX NASDAQ:RIGL NASDAQ:ZBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINVAInnoviva$22.46$22.90$16.52▼$25.15$1.66B0.38684,891 shs1.19 million shsNVAXNovavax$9.21$8.83$6.13▼$11.97$1.51B2.375.47 million shs4.42 million shsRIGLRigel Pharmaceuticals$29.01$28.55$18.14▼$52.24$536.69M1.21442,511 shs183,368 shsZBIOZenas BioPharma$18.97$20.40$8.91▼$44.60$1.20B-0.61555,534 shs342,230 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINVAInnoviva0.00%+2.23%-4.71%-4.06%+18.40%NVAXNovavax0.00%+1.66%+12.04%-1.60%+27.03%RIGLRigel Pharmaceuticals0.00%0.00%-4.23%-15.32%+53.09%ZBIOZenas BioPharma0.00%+3.44%+4.29%-27.43%+65.97%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINVAInnoviva$22.46$22.90$16.52▼$25.15$1.66B0.38684,891 shs1.19 million shsNVAXNovavax$9.21$8.83$6.13▼$11.97$1.51B2.375.47 million shs4.42 million shsRIGLRigel Pharmaceuticals$29.01$28.55$18.14▼$52.24$536.69M1.21442,511 shs183,368 shsZBIOZenas BioPharma$18.97$20.40$8.91▼$44.60$1.20B-0.61555,534 shs342,230 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINVAInnoviva0.00%+2.23%-4.71%-4.06%+18.40%NVAXNovavax0.00%+1.66%+12.04%-1.60%+27.03%RIGLRigel Pharmaceuticals0.00%0.00%-4.23%-15.32%+53.09%ZBIOZenas BioPharma0.00%+3.44%+4.29%-27.43%+65.97%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINVAInnoviva 2.57Moderate Buy$36.2061.18% UpsideNVAXNovavax 2.10Hold$12.1331.65% UpsideRIGLRigel Pharmaceuticals 2.33Hold$54.5087.87% UpsideZBIOZenas BioPharma 2.56Moderate Buy$44.29133.45% UpsideCurrent Analyst Ratings BreakdownLatest RIGL, INVA, NVAX, and ZBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026RIGLRigel Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$57.005/15/2026ZBIOZenas BioPharma Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/15/2026ZBIOZenas BioPharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$44.005/14/2026ZBIOZenas BioPharma Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$21.00 ➝ $22.005/14/2026ZBIOZenas BioPharma CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/13/2026RIGLRigel Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$69.00 ➝ $81.005/7/2026NVAXNovavax Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D)5/7/2026INVAInnoviva BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$35.00 ➝ $42.005/7/2026RIGLRigel Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/7/2026RIGLRigel Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$71.00 ➝ $69.005/6/2026NVAXNovavax TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$8.00 ➝ $9.00(Data available from 5/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINVAInnoviva$411.33M4.03$5.04 per share4.46$18.18 per share1.24NVAXNovavax$596.34M2.54$3.52 per share2.62($0.88) per share-10.47RIGLRigel Pharmaceuticals$294.28M1.82$6.75 per share4.30$21.61 per share1.34ZBIOZenas BioPharma$10M119.76N/AN/A$5.32 per share3.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINVAInnoviva$271.17M$6.013.748.98N/A119.89%33.33%22.67%8/5/2026 (Estimated)NVAXNovavax$440.30M-$0.58N/AN/AN/A-14.73%-14.82%1.23%8/5/2026 (Estimated)RIGLRigel Pharmaceuticals$367.02M$18.721.558.66N/A121.50%47.99%32.40%8/4/2026 (Estimated)ZBIOZenas BioPharma-$377.74M-$8.47N/AN/AN/AN/A-99.99%-58.06%8/11/2026 (Estimated)Latest RIGL, INVA, NVAX, and ZBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026ZBIOZenas BioPharma-$1.4742-$1.46+$0.0142-$1.46$25.00 millionN/A5/6/2026Q1 2026INVAInnoviva$0.43$0.44+$0.01$2.22$101.57 million$97.99 million5/6/2026Q1 2026NVAXNovavax-$0.25-$0.06+$0.19-$0.06$79.81 million$118.90 million5/5/2026Q1 2026RIGLRigel Pharmaceuticals$0.7950$0.44-$0.3550$0.44$62.40 million$58.82 million4/13/2026Q4 2025ZBIOZenas BioPharmaN/A-$1.10N/A-$0.98$40.00 millionN/A3/16/2026Q4 2025ZBIOZenas BioPharma-$1.22-$4.54-$3.32-$4.54$28.75 millionN/A3/3/2026Q4 2025RIGLRigel Pharmaceuticals$1.33$1.14-$0.19$13.54$68.70 million$69.80 million2/26/2026Q4 2025NVAXNovavax-$0.66$0.11+$0.77$0.11$90.26 million$136.40 million2/25/2026Q4 2025INVAInnoviva$0.34$1.94+$1.60$1.94$102.62 million$114.61 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthINVAInnovivaN/AN/AN/AN/AN/ANVAXNovavaxN/AN/AN/AN/AN/ARIGLRigel PharmaceuticalsN/AN/AN/AN/AN/AZBIOZenas BioPharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINVAInnoviva0.1921.1320.07NVAXNovavaxN/A2.482.45RIGLRigel Pharmaceuticals0.042.622.48ZBIOZenas BioPharma1.0411.9411.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINVAInnoviva99.12%NVAXNovavax53.04%RIGLRigel Pharmaceuticals66.23%ZBIOZenas BioPharmaN/AInsider OwnershipCompanyInsider OwnershipINVAInnoviva2.01%NVAXNovavax1.00%RIGLRigel Pharmaceuticals10.47%ZBIOZenas BioPharma22.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINVAInnoviva10073.81 million72.33 millionOptionableNVAXNovavax1,990164.44 million162.79 millionOptionableRIGLRigel Pharmaceuticals16018.50 million16.57 millionOptionableZBIOZenas BioPharmaN/A63.13 million49.24 millionN/ARIGL, INVA, NVAX, and ZBIO HeadlinesRecent News About These CompaniesZenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 ...May 19, 2026 | markets.businessinsider.comHC Wainwright Predicts Lower Earnings for Zenas BioPharmaMay 19, 2026 | marketbeat.comZenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 CongressMay 19, 2026 | globenewswire.comZenas BioPharma (NASDAQ:ZBIO) CEO Leon Moulder, Jr. Purchases 60,000 SharesMay 19, 2026 | americanbankingnews.comZenas BioPharma (NASDAQ:ZBIO) CEO Purchases $1,012,800.00 in StockMay 19, 2026 | insidertrades.comZenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 18, 2026 | globenewswire.comZenas BioPharma Advances Phase 3 Orelabrutinib Trial in Tough MS SegmentMay 18, 2026 | tipranks.comHead to Head Review: Zenas BioPharma (NASDAQ:ZBIO) vs. Elicio Therapeutics (NASDAQ:ELTX)May 18, 2026 | americanbankingnews.comVanguard Group Inc. Acquires 290,307 Shares of Zenas BioPharma, Inc. $ZBIOMay 16, 2026 | marketbeat.comZenas BioPharma (NASDAQ:ZBIO) Raised to Sell at Wall Street ZenMay 16, 2026 | americanbankingnews.comZenas BioPharma, Inc. (NASDAQ:ZBIO) Receives Consensus Recommendation of "Hold" from AnalystsMay 15, 2026 | americanbankingnews.comWhy Zenas BioPharma (ZBIO) Is Down 7.7% After Reporting a Sharply Wider Quarterly Net LossMay 14, 2026 | uk.finance.yahoo.comZenas BioPharma Stock Short Interest Report | NASDAQ:ZBIO | BenzingaMay 13, 2026 | benzinga.comZenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF InhibitorMay 13, 2026 | globenewswire.comZenas BioPharma Highlights Strong Q1 Progress and FinancingMay 13, 2026 | tipranks.comZenas BioPharma Reports Progress on Obexelimab and ZB021 Trials, Financial Milestones and Upcoming Regulatory SubmissionsMay 13, 2026 | quiverquant.comQZenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 13, 2026 | globenewswire.comZenas BioPharma (ZBIO) to Release Quarterly Earnings on ThursdayMay 7, 2026 | marketbeat.comZenas BioPharma (NASDAQ:ZBIO) Stock Price Up 7.7% - Still a Buy?May 4, 2026 | marketbeat.comZenas BioPharma rises as CEO continues insider purchasesApril 30, 2026 | msn.comZenas: 'Strong Buy' On Obexelimab Enhancement And Expected SLE Data Q4 2026April 30, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRIGL, INVA, NVAX, and ZBIO Company DescriptionsInnoviva NASDAQ:INVA$22.46 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$22.25 -0.21 (-0.93%) As of 05/22/2026 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.Novavax NASDAQ:NVAX$9.21 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$9.20 -0.01 (-0.05%) As of 05/22/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.Rigel Pharmaceuticals NASDAQ:RIGL$29.01 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$29.03 +0.02 (+0.07%) As of 05/22/2026 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.Zenas BioPharma NASDAQ:ZBIO$18.97 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$19.05 +0.08 (+0.42%) As of 05/22/2026 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Ross Stores Earnings Beat Sends Stock To New Highs Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins Apparel Earnings Winners and Losers: Ralph Lauren Takes Off SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? The Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May Appear Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
